ArriVent BioPharma/$AVBP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ArriVent BioPharma
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
- Ticker
- $AVBP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Newtown Square, United States
- Website
- arrivent.com
AVBP Metrics
BasicAdvanced
$1.5bn
-
-$3.52
1.52
-
Price and volume
Market cap
$1.5bn
Beta
1.52
52-week high
$35.83
52-week low
$16.65
Average daily volume
476k
Financial strength
Current ratio
13.951
Quick ratio
13.058
Long term debt to equity
0.099
Total debt to equity
0.129
Profitability
Management effectiveness
Return on assets (TTM)
-34.72%
Return on equity (TTM)
-55.17%
Valuation
Price to book
4.4
Price to tangible book (TTM)
4.4
Price to free cash flow (TTM)
-9.652
Free cash flow yield (TTM)
-10.36%
Free cash flow per share (TTM)
-3.26
Growth
Earnings per share change (TTM)
-6.96%
3-year earnings per share growth (CAGR)
-52.38%
What the Analysts think about AVBP
Analyst ratings (Buy, Hold, Sell) for ArriVent BioPharma stock.
AVBP Financial Performance
Revenues and expenses
AVBP Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.